Includes bibliographical references (p. 203-214)Sansalvamide A (SanA) is a cyclic depsipeptide that was isolated from a marine fungus and demonstrates mid-micromolar anti-cancer activity in the NCI 60-cell line panel. Our laboratory has synthesized over 100 peptide derivatives of this molecule, 5 of which were contributed by the author of this dissertation. The design and solution-phase synthesis of these derivatives is described in Chapter 2. The author was also responsible for attaching PEG-biotin and fluorescein tags to lead SanA derivatives to be used in mechanism of action studies. Chapter 3 describes the mechanism of action studies that were completed with the lead derivatives, both untagged and tagged with PEG-biotin or fluorescein. ...
Includes bibliographical references (p. 54-57).Heat Shock Protein 90 (Hsp90) is a molecular chaperon...
Chapter 1. The first chapter discusses the background of peptides and their potential as drugs. The ...
This thesis describes the development of two anticancer drug leads from macrocyclic peptide-based ...
Sansalvamide A (SanA) is a cyclic depsipeptide that was isolated from a marine fungus and demonstrat...
Includes bibliographical references (p. 88-94)Sansalvamide A (SanA) is a cyclic depsipeptide isolate...
This thesis describes the biological evaluation and synthetic development of derivatives of the natu...
Abstract: Utilizing the structure-activity relationship we have developed during the synthesis of th...
Includes bibliographical references (p. 118-123)Natural products have been the source of valuable le...
This thesis describes the development of lead structures from two macrocyclic peptide-based natural ...
Includes bibliographical references.Chapter 1 discusses the background of peptides and their potenti...
Described are the syntheses of 3 Sansalvamide A derivatives that contain biotinylated tags at indivi...
Chapter 1. The background of peptides as therapeutics and anti-cancer agents is discussed in this ch...
Chapter 1 discusses the background of peptides and their potential as therapeutics; specifically as ...
Includes bibliographical references.Chapter 1. The first chapter discusses the background of peptide...
Includes bibliographical referencesChapter 1\ud The background of peptides as therapeutics and anti-...
Includes bibliographical references (p. 54-57).Heat Shock Protein 90 (Hsp90) is a molecular chaperon...
Chapter 1. The first chapter discusses the background of peptides and their potential as drugs. The ...
This thesis describes the development of two anticancer drug leads from macrocyclic peptide-based ...
Sansalvamide A (SanA) is a cyclic depsipeptide that was isolated from a marine fungus and demonstrat...
Includes bibliographical references (p. 88-94)Sansalvamide A (SanA) is a cyclic depsipeptide isolate...
This thesis describes the biological evaluation and synthetic development of derivatives of the natu...
Abstract: Utilizing the structure-activity relationship we have developed during the synthesis of th...
Includes bibliographical references (p. 118-123)Natural products have been the source of valuable le...
This thesis describes the development of lead structures from two macrocyclic peptide-based natural ...
Includes bibliographical references.Chapter 1 discusses the background of peptides and their potenti...
Described are the syntheses of 3 Sansalvamide A derivatives that contain biotinylated tags at indivi...
Chapter 1. The background of peptides as therapeutics and anti-cancer agents is discussed in this ch...
Chapter 1 discusses the background of peptides and their potential as therapeutics; specifically as ...
Includes bibliographical references.Chapter 1. The first chapter discusses the background of peptide...
Includes bibliographical referencesChapter 1\ud The background of peptides as therapeutics and anti-...
Includes bibliographical references (p. 54-57).Heat Shock Protein 90 (Hsp90) is a molecular chaperon...
Chapter 1. The first chapter discusses the background of peptides and their potential as drugs. The ...
This thesis describes the development of two anticancer drug leads from macrocyclic peptide-based ...